Bicara Therapeutics (BCAX) News Today $11.88 -0.70 (-5.56%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$11.88 0.00 (0.00%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock BCAX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period Analysts Issue Forecasts for BCAX FY2026 EarningsJune 12 at 3:33 AM | americanbankingnews.comBicara Therapeutics (NASDAQ:BCAX) Stock Price Down 4.6% - What's Next?Bicara Therapeutics (NASDAQ:BCAX) Trading Down 4.6% - Time to Sell?June 11 at 3:18 PM | marketbeat.comBicara Therapeutics Inc. (NASDAQ:BCAX) Holdings Raised by Bank of America Corp DEBank of America Corp DE grew its position in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 278.4% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 33,677 shares of the company's stock after acquiring an additional 2June 11 at 3:10 AM | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Stock Price Up 6.7% - Here's WhyBicara Therapeutics (NASDAQ:BCAX) Trading 6.7% Higher - Still a Buy?June 10 at 11:57 AM | marketbeat.comEquities Analysts Offer Predictions for BCAX FY2026 EarningsBicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Cantor Fitzgerald issued their FY2026 earnings per share (EPS) estimates for shares of Bicara Therapeutics in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst E. Schmidt anticipates that the company will post earnings ofJune 10 at 9:17 AM | marketbeat.comBCAX Bicara Therapeutics Inc.June 8, 2025 | seekingalpha.comBicara Therapeutics Expands Boston Headquarters with New LeaseJune 6, 2025 | tipranks.com25,028 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Purchased by Nuveen Asset Management LLCNuveen Asset Management LLC purchased a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 25,028 shares of the company's stock, valued at apJune 6, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Sees Large Volume Increase - Still a Buy?Bicara Therapeutics (NASDAQ:BCAX) Sees Unusually-High Trading Volume - Should You Buy?June 4, 2025 | marketbeat.comBicara Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare ConferenceJune 3, 2025 | globenewswire.comBicara Therapeutics (NASDAQ:BCAX) Trading 7.5% Higher - Time to Buy?Bicara Therapeutics (NASDAQ:BCAX) Trading Up 7.5% - Should You Buy?June 3, 2025 | marketbeat.comBicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025June 1, 2025 | globenewswire.comBicara Therapeutics Inc. (NASDAQ:BCAX) Shares Bought by Millennium Management LLCMillennium Management LLC boosted its holdings in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 28.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 385,406 shares of the company'sMay 28, 2025 | marketbeat.comStifel Reaffirms Buy Rating on BCAX After Promising ASCO Data for HPV-Negative PatientsMay 26, 2025 | insidermonkey.com112,476 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Acquired by Deutsche Bank AGDeutsche Bank AG acquired a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The fund acquired 112,476 shares of the company's stock, valued at approximately $1,959,000. Deutsche Bank AG owneMay 26, 2025 | marketbeat.com159,043 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Purchased by Northern Trust CorpNorthern Trust Corp acquired a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 159,043 shares of the company's stock,May 26, 2025 | marketbeat.comBicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Recommendation of "Buy" from BrokeragesShares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) have been given a consensus rating of "Buy" by the nine ratings firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold recommendation, seven have assigned a buyMay 26, 2025 | marketbeat.comWells Fargo & Company Upgrades Bicara Therapeutics (NASDAQ:BCAX) to Equal WeightWells Fargo & Company raised Bicara Therapeutics from an "underweight" rating to an "equal weight" rating and set a $8.00 price target on the stock in a research note on Friday.May 25, 2025 | marketbeat.comWedbush Reaffirms "Outperform" Rating for Bicara Therapeutics (NASDAQ:BCAX)Wedbush reaffirmed an "outperform" rating and issued a $30.00 target price on shares of Bicara Therapeutics in a research report on Friday.May 25, 2025 | marketbeat.comWells Fargo Upgrades Bicara Therapeutics (BCAX)May 24, 2025 | msn.comBicara Therapeutics to present head and neck cancer study dataMay 23, 2025 | investing.comBicara Therapeutics Shares Sink Over 43% On Mixed Phase 1/1b Trial Results: What's Going On?May 23, 2025 | benzinga.comMerus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara TherapeuticsMay 23, 2025 | msn.comBicara falls after early-stage trial data for head and neck cancer therapyMay 23, 2025 | msn.comBicara Therapeutics stock tumbles on clinical trial dataMay 23, 2025 | in.investing.comBicara Therapeutics Announces Publication of an Abstract with Updated Interim Data from Phase 1/1b Trial of Ficerafusp alfa in 1L R/M HNSCC at the 2025 ASCO Annual MeetingMay 22, 2025 | globenewswire.comWexford Capital LP Makes New Investment in Bicara Therapeutics Inc. (NASDAQ:BCAX)Wexford Capital LP purchased a new position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 20,000 shares of the compaMay 22, 2025 | marketbeat.comVestal Point Capital LP Raises Stock Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)Vestal Point Capital LP boosted its holdings in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 67.1% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 710,000 shares of the company's stock after buying an additional 285,000 shares duMay 21, 2025 | marketbeat.comJanus Henderson Group PLC Reduces Stock Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)Janus Henderson Group PLC lowered its stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 27.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 863,846 shares of the company's stock after selling 324,345 sharesMay 19, 2025 | marketbeat.comMaven Securities LTD Has $436,000 Stock Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)Maven Securities LTD reduced its stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 50.0% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 25,000 shares of the company's stock after sellMay 16, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Shares Down 8.7% After Earnings MissBicara Therapeutics (NASDAQ:BCAX) Stock Price Down 8.7% After Earnings MissMay 15, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Releases Quarterly Earnings Results, Misses Estimates By $0.28 EPSBicara Therapeutics (NASDAQ:BCAX - Get Free Report) announced its earnings results on Tuesday. The company reported ($0.68) EPS for the quarter, missing the consensus estimate of ($0.40) by ($0.28).May 15, 2025 | marketbeat.comOrbimed Advisors LLC Grows Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)Orbimed Advisors LLC lifted its position in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 9.7% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 298,301 shares of the company's stock after purchasing an additional 26,391 shares during the period.May 15, 2025 | marketbeat.comBicara Therapeutics Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comBarclays PLC Buys 20,107 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX)Barclays PLC boosted its position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 201.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,107 shares of the company's stock after acMay 11, 2025 | marketbeat.comDAFNA Capital Management LLC Takes $1.84 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)DAFNA Capital Management LLC acquired a new stake in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 105,500 shares of the company's stock, valued at aMay 10, 2025 | marketbeat.comDeep Track Capital LP Has $34.84 Million Stock Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)Deep Track Capital LP lifted its stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 151.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,000,000 shares of the cMay 9, 2025 | marketbeat.comBraidwell LP Has $34.85 Million Stock Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)Braidwell LP raised its position in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 20.7% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 2,000,659 shares of the company's stock after acquiring an additional 343,059 shares during the period. BraidMay 8, 2025 | marketbeat.comBlackstone Inc. Acquires 263,060 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX)Blackstone Inc. boosted its holdings in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 40.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 913,060 shares of the company's stock aftMay 8, 2025 | marketbeat.com643,381 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Bought by Acorn Capital Advisors LLCAcorn Capital Advisors LLC bought a new position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 643,381 shares of the company's stMay 4, 2025 | marketbeat.comBoxer Capital Management LLC Acquires New Holdings in Bicara Therapeutics Inc. (NASDAQ:BCAX)Boxer Capital Management LLC purchased a new position in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund purchased 135,000 shares of the company's stock, valued at approxMay 4, 2025 | marketbeat.comBicara Therapeutics (NASDAQ:BCAX) Sets New 52-Week High - Here's WhyBicara Therapeutics (NASDAQ:BCAX) Hits New 12-Month High - Time to Buy?May 3, 2025 | marketbeat.comWedbush Expects Stronger Earnings for Bicara TherapeuticsBicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Investment analysts at Wedbush upped their FY2028 EPS estimates for Bicara Therapeutics in a research report issued to clients and investors on Sunday, April 27th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($2.0May 2, 2025 | marketbeat.comBicara Therapeutics Inc. (NASDAQ:BCAX) Receives Consensus Rating of "Moderate Buy" from BrokeragesBicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) has been given an average recommendation of "Moderate Buy" by the nine ratings firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, seven have given a buy recMay 2, 2025 | marketbeat.comMarshall Wace LLP Takes $1.18 Million Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)Marshall Wace LLP acquired a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 67,733 shares of the compMay 2, 2025 | marketbeat.comBicara Therapeutics Presents Promising Data for Ficerafusp Alfa at AACR Annual Meeting 2025May 1, 2025 | nasdaq.comBicara Therapeutics (NASDAQ:BCAX) Trading Down 2.8% - Should You Sell?Bicara Therapeutics (NASDAQ:BCAX) Trading Down 2.8% - What's Next?April 30, 2025 | marketbeat.com950,000 Shares in Bicara Therapeutics Inc. (NASDAQ:BCAX) Purchased by Foresite Capital Management VI LLCForesite Capital Management VI LLC purchased a new position in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 950,000 shares of thApril 30, 2025 | marketbeat.comJPMorgan Chase & Co. Buys 64,010 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX)JPMorgan Chase & Co. lifted its position in Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) by 8,768.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 64,740 shares of the comApril 29, 2025 | marketbeat.comBicara Therapeutics Highlights Broad Potential of Ficerafusp Alfa at AACR Annual Meeting 2025April 28, 2025 | globenewswire.com Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Email Address BCAX Media Mentions By Week BCAX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCAX News Sentiment▼1.100.91▲Average Medical News Sentiment BCAX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCAX Articles This Week▼124▲BCAX Articles Average Week Get Bicara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCAX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies NAMS News Today BLTE News Today HRMY News Today KNSA News Today VCEL News Today DNLI News Today CGON News Today VERA News Today IMCR News Today GLPG News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCAX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | SponsoredBillionaires are piling into this gold investmentBillionaires Are Piling into a Special Gold Investment With record gold prices, everyday Americans are scra...Weiss Ratings | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicara Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BCAX Stock Free BCAX Stock Alerts